Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
27 Oct 2024
27 Oct 2024
Historique:
received:
26
10
2023
accepted:
19
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Alpha-synuclein (α-syn) inclusions in the brain are hallmarks of so-called Lewy body diseases. Lewy bodies contain mainly aggregated α-syn together with some other proteins. Monomeric α-syn lacks a well-defined three-dimensional structure, but it can aggregate into oligomeric and fibrillar amyloid species, which can be detected using specific antibodies. Here we investigate the aggregate specificity of monoclonal MJFR14-6-4-2 antibodies. We conclude that partial masking of epitope in unstructured monomer in combination with a high local concentration of epitopes is the main reason for MJFR14-6-4-2 selectivity towards aggregates. Based on the structural insight, we produced mutant α-syn that when fibrillated is unable to bind MJFR14-6-4-2. Using these fibrils as a tool for seeding cellular α-syn aggregation, provides superior signal/noise ratio for detection of cellular α-syn aggregates by MJFR14-6-4-2. Our data provide a molecular level understanding of specific recognition of toxic amyloid oligomers, which is critical for the development of inhibitors against synucleinopathies.
Identifiants
pubmed: 39463404
doi: 10.1038/s41531-024-00822-y
pii: 10.1038/s41531-024-00822-y
doi:
Types de publication
Journal Article
Langues
eng
Pagination
206Informations de copyright
© 2024. The Author(s).
Références
Bendor, J. T., Logan, T. P. & Edwards, R. H. The function of alpha-synuclein. Neuron 79, 1044–1066 (2013).
pubmed: 24050397
doi: 10.1016/j.neuron.2013.09.004
Ramalingam, N. et al. Dynamic physiological alpha-synuclein S129 phosphorylation is driven by neuronal activity. NPJ Parkinsons Dis. 9, 4 (2023).
pubmed: 36646701
pmcid: 9842642
doi: 10.1038/s41531-023-00444-w
Somayaji, M. et al. A dual role for alpha-synuclein in facilitation and depression of dopamine release from substantia nigra neurons in vivo. Proc. Natl Acad. Sci. USA 117, 32701–32710 (2020).
pubmed: 33273122
pmcid: 7768743
doi: 10.1073/pnas.2013652117
Calabresi, P. et al. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 14, 176 (2023).
pubmed: 36859484
pmcid: 9977911
doi: 10.1038/s41419-023-05672-9
Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839–840 (1997).
pubmed: 9278044
doi: 10.1038/42166
Wakabayashi, K. et al. The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27, 494–506 (2007).
pubmed: 18018486
doi: 10.1111/j.1440-1789.2007.00803.x
Lashuel, H. A. et al. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38–48 (2013).
pubmed: 23254192
pmcid: 4295774
doi: 10.1038/nrn3406
Outeiro, T. F. & Lindquist, S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 1772–1775 (2003).
pubmed: 14657500
pmcid: 1780172
doi: 10.1126/science.1090439
Stefanis, L. alpha-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2, a009399 (2012).
pubmed: 22355802
pmcid: 3281589
doi: 10.1101/cshperspect.a009399
Jellinger, K. A. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys. Acta 1792, 730–740 (2009).
pubmed: 18718530
doi: 10.1016/j.bbadis.2008.07.006
Postuma, R. B. et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142, 744–759 (2019).
pubmed: 30789229
pmcid: 6391615
doi: 10.1093/brain/awz030
Athauda, D. & Foltynie, T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat. Rev. Neurol. 11, 25–40 (2015).
pubmed: 25447485
doi: 10.1038/nrneurol.2014.226
Brundin, P., Dave, K. D. & Kordower, J. H. Therapeutic approaches to target alpha-synuclein pathology. Exp. Neurol. 298, 225–235 (2017).
pubmed: 28987463
pmcid: 6541231
doi: 10.1016/j.expneurol.2017.10.003
Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18, 435–450 (2017).
pubmed: 28592904
doi: 10.1038/nrn.2017.62
Mollenhauer, B. et al. A user’s guide for alpha-synuclein biomarker studies in biological fluids: Perianalytical considerations. Mov. Disord. 32, 1117–1130 (2017).
pubmed: 28734051
pmcid: 5638072
doi: 10.1002/mds.27090
Olanow, C. W. et al. Temporal evolution of microglia and alpha-synuclein accumulation following foetal grafting in Parkinson’s disease. Brain 142, 1690–1700 (2019).
pubmed: 31056668
doi: 10.1093/brain/awz104
Lassen, L. B. et al. ELISA method to detect alpha-synuclein oligomers in cell and animal models. PLoS One 13, e0196056 (2018).
pubmed: 29698510
pmcid: 5919555
doi: 10.1371/journal.pone.0196056
Lassen, L. B. et al. Mutation of Tyrosine Sites in the Human Alpha-Synuclein Gene Induces Neurotoxicity in Transgenic Mice with Soluble Alpha-Synuclein Oligomer Formation. Cells 11, 3673 (2022).
pubmed: 36429099
pmcid: 9688722
doi: 10.3390/cells11223673
Ludtmann, M. H. R. et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease. Nat. Commun. 9, 2293 (2018).
pubmed: 29895861
pmcid: 5997668
doi: 10.1038/s41467-018-04422-2
Ferreira, N. et al. Multiple system atrophy-associated oligodendroglial protein p25alpha stimulates formation of novel alpha-synuclein strain with enhanced neurodegenerative potential. Acta Neuropathol. 142, 87–115 (2021).
pubmed: 33978813
pmcid: 8217051
doi: 10.1007/s00401-021-02316-0
Mavroeidi, P. et al. Endogenous oligodendroglial alpha-synuclein and TPPP/p25alpha orchestrate alpha-synuclein pathology in experimental multiple system atrophy models. Acta Neuropathol. 138, 415–441 (2019).
pubmed: 31011860
pmcid: 7289399
doi: 10.1007/s00401-019-02014-y
Ghanem, S. S. et al. alpha-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc. Natl Acad. Sci. USA 119, e2109617119 (2022).
pubmed: 35353605
pmcid: 9169642
doi: 10.1073/pnas.2109617119
Yu, Z. et al. Erythrocytic alpha-Synuclein Species for Parkinson’s Disease Diagnosis and the Correlations With Clinical Characteristics. Front Aging Neurosci. 14, 827493 (2022).
pubmed: 35185529
pmcid: 8850836
doi: 10.3389/fnagi.2022.827493
Kumar, S. T. et al. How specific are the conformation-specific alpha-synuclein antibodies? Characterization and validation of 16 alpha-synuclein conformation-specific antibodies using well-characterized preparations of alpha-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol. Dis. 146, 105086 (2020).
pubmed: 32971232
doi: 10.1016/j.nbd.2020.105086
Pumpens, P. & Puskho, P. Virus-Like Particles: A Comprehensive Guide. 2022: CRC Press.
Bachmann, M. F. et al. The influence of antigen organization on B cell responsiveness. Science 262, 1448–1451 (1993).
pubmed: 8248784
doi: 10.1126/science.8248784
Spohn, G. et al. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J. Immunol. 175, 6211–6218 (2005).
pubmed: 16237119
doi: 10.4049/jimmunol.175.9.6211
Pumpens, P. et al. The True Story and Advantages of RNA Phage Capsids as Nanotools. Intervirology 59, 74–110 (2016).
pubmed: 27829245
doi: 10.1159/000449503
Shishovs, M. et al. Structure of AP205 Coat Protein Reveals Circular Permutation in ssRNA Bacteriophages. J. Mol. Biol. 428, 4267–4279 (2016).
pubmed: 27591890
doi: 10.1016/j.jmb.2016.08.025
Doucet, M. et al. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS One 12, e0181844 (2017).
pubmed: 28797124
pmcid: 5552317
doi: 10.1371/journal.pone.0181844
Bussell, R. Jr. & Eliezer, D. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol. 329, 763–778 (2003).
pubmed: 12787676
doi: 10.1016/S0022-2836(03)00520-5
Eliezer, D. et al. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061–1073 (2001).
pubmed: 11286556
doi: 10.1006/jmbi.2001.4538
Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739–29752 (2006).
pubmed: 16847063
doi: 10.1074/jbc.M600933200
Paleologou, K. E. et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 283, 16895–16905 (2008).
pubmed: 18343814
pmcid: 2423264
doi: 10.1074/jbc.M800747200
Kartal, O. et al. waveRAPID-A Robust Assay for High-Throughput Kinetic Screens with the Creoptix WAVEsystem. SLAS Discov. 26, 995–1003 (2021).
pubmed: 34049465
doi: 10.1177/24725552211013827
De Genst, E. J. et al. Structure and properties of a complex of alpha-synuclein and a single-domain camelid antibody. J. Mol. Biol. 402, 326–343 (2010).
pubmed: 20620148
doi: 10.1016/j.jmb.2010.07.001
Wang, Y. & Jardetzky, O. Probability-based protein secondary structure identification using combined NMR chemical-shift data. Protein Sci. 11, 852–861 (2002).
pubmed: 11910028
pmcid: 2373532
doi: 10.1110/ps.3180102
Iwadate, M., Asakura, T. & Williamson, M. P. C alpha and C beta carbon-13 chemical shifts in proteins from an empirical database. J. Biomol. NMR 13, 199–211 (1999).
pubmed: 10212983
doi: 10.1023/A:1008376710086
Polinski, N. K. et al. Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents. J. Parkinsons Dis. 8, 303–322 (2018).
pubmed: 29400668
pmcid: 6004926
doi: 10.3233/JPD-171248
Quintin, S. et al. Cellular processing of alpha-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114. J. Biol. Chem. 299, 104912 (2023).
pubmed: 37307916
pmcid: 10404685
doi: 10.1016/j.jbc.2023.104912
Elfarrash, S. et al. Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates. Acta Neuropathol. Commun. 7, 213 (2019).
pubmed: 31856920
pmcid: 6924077
doi: 10.1186/s40478-019-0865-5
Elfarrash, S. et al. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein. PLoS One 16, e0252635 (2021).
pubmed: 34613964
pmcid: 8494365
doi: 10.1371/journal.pone.0252635
Games, D. et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J. Neurosci. 34, 9441–9454 (2014).
pubmed: 25009275
pmcid: 4087215
doi: 10.1523/JNEUROSCI.5314-13.2014
Masliah, E. et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6, e19338 (2011).
pubmed: 21559417
pmcid: 3084838
doi: 10.1371/journal.pone.0019338
Tran, H. T. et al. Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep. 7, 2054–2065 (2014).
pubmed: 24931606
pmcid: 4410967
doi: 10.1016/j.celrep.2014.05.033
Schofield, D. J. et al. Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol. Dis. 132, 104582 (2019).
pubmed: 31445162
doi: 10.1016/j.nbd.2019.104582
Weihofen, A. et al. Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol. Dis. 124, 276–288 (2019).
pubmed: 30381260
doi: 10.1016/j.nbd.2018.10.016
Pagano, G. et al. Trial of Prasinezumab in Early-Stage Parkinson’s Disease. N. Engl. J. Med. 387, 421–432 (2022).
pubmed: 35921451
doi: 10.1056/NEJMoa2202867
Lang, A. E. et al. Trial of Cinpanemab in Early Parkinson’s Disease. N. Engl. J. Med. 387, 408–420 (2022).
pubmed: 35921450
doi: 10.1056/NEJMoa2203395
Toleikis, Z. et al. S100A9 Alters the Pathway of Alpha-Synuclein Amyloid Aggregation. Int J. Mol. Sci. 22, 7972 (2021).
pubmed: 34360737
pmcid: 8348003
doi: 10.3390/ijms22157972
De Giorgi, F. et al. Neurons with Cat’s Eyes: A Synthetic Strain of alpha-Synuclein Fibrils Seeding Neuronal Intranuclear Inclusions. Biomolecules 12, 436 (2022).
pubmed: 35327628
pmcid: 8946814
doi: 10.3390/biom12030436
Betzer, C. et al. Identification of synaptosomal proteins binding to monomeric and oligomeric alpha-synuclein. PLoS One 10, e0116473 (2015).
pubmed: 25659148
pmcid: 4319895
doi: 10.1371/journal.pone.0116473
Lieknina, I. et al. Novel ssRNA phage VLP platform for displaying foreign epitopes by genetic fusion. Vaccine 38, 6019–6026 (2020).
pubmed: 32713683
doi: 10.1016/j.vaccine.2020.07.016
Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D. Biol. Crystallogr 67, 293–302 (2011).
pubmed: 21460447
pmcid: 3069744
doi: 10.1107/S0907444911007773
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr 40, 658–674 (2007).
pubmed: 19461840
pmcid: 2483472
doi: 10.1107/S0021889807021206
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol. Crystallogr 60, 2126–2132 (2004).
pubmed: 15572765
doi: 10.1107/S0907444904019158
Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D. Biol. Crystallogr. 53, 240–255 (1997).
pubmed: 15299926
doi: 10.1107/S0907444996012255
Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687–696 (2005).
pubmed: 15815974
doi: 10.1002/prot.20449
Porcari, R. et al. The H50Q mutation induces a 10-fold decrease in the solubility of alpha-synuclein. J. Biol. Chem. 290, 2395–2404 (2015).
pubmed: 25505181
doi: 10.1074/jbc.M114.610527
Reimer, L. et al. Protein kinase R dependent phosphorylation of alpha-synuclein regulates its membrane binding and aggregation. PNAS Nexus 1, pgac259 (2022).
pubmed: 36712380
pmcid: 9802061
doi: 10.1093/pnasnexus/pgac259